{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T06:04:22Z","timestamp":1783749862266,"version":"3.55.0"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012938","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000}}],"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["W15QKN-16-9-1002"],"award-info":[{"award-number":["W15QKN-16-9-1002"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI171292-01"],"award-info":[{"award-number":["U19AI171292-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P51OD011092"],"award-info":[{"award-number":["P51OD011092"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>O\u2019nyong-nyong virus (ONNV) is a mosquito-transmitted alphavirus identified in Uganda in 1959. The virus has potential for enzootic and urban transmission cycles, and in humans, ONNV infection manifests as fever, rash, and joint\/muscle pain that can persist. There are currently no specific vaccines or antiviral treatments for ONNV. Since highly passaged alphaviruses often lose pathogenic features, we constructed an infectious clone for ONNV-UVRI0804 (ONNV<jats:sub>0804<\/jats:sub>), a 2017 isolate from a febrile patient in Uganda. Viral replication for ONNV<jats:sub>0804<\/jats:sub> was compared to the highly passaged strain, ONNV<jats:sub>UgMP30<\/jats:sub>, and ONNV<jats:sub>UgMP30<\/jats:sub> replicated to higher levels in human dermal fibroblasts and Vero cells, but both viruses replicated similarly in C6\/36 and mouse embryonic fibroblast cells. We performed a head-to-head comparison of <jats:italic>in vivo<\/jats:italic> virulence in both immunocompetent C57BL\/6 mice and interferon deficient AG129 mice. In both mouse strains, ONNV<jats:sub>0804<\/jats:sub> was substantially more pathogenic than ONNV<jats:sub>UgMP30<\/jats:sub>. Unlike ONNV<jats:sub>UgMP30<\/jats:sub>, ONNV<jats:sub>0804<\/jats:sub> caused significant footpad swelling and broader tissue distribution with higher vRNA loads at both 5- and 43-days post-infection (dpi) relative to ONNV<jats:sub>UgMP30<\/jats:sub>. This finding indicates that ONNV can persist in joint and muscle tissues for long periods of time, which has been associated with chronic arthritogenic human disease. In AG129 mice, ONNV<jats:sub>0804<\/jats:sub> caused a more rapid onset of disease, higher viremia, and a &gt;800-fold increase in virulence. Previous studies have shown that CHIKV infection or vaccination can provide cross-reactive immunity to ONNV. To determine if a CHIKV vaccine can protect against the more virulent ONNV<jats:sub>0804<\/jats:sub> strain, we vaccinated mice with a hydrogen peroxide-inactivated CHIKV vaccine, HydroVax-CHIKV. Neutralizing antibody titers were determined against ONNV<jats:sub>0804<\/jats:sub> and CHIKV and animals were challenged with ONNV<jats:sub>0804<\/jats:sub>. An optimized two-dose vaccination regimen of HydroVax-CHIKV protected against lethal infection and reduced virus-associated arthritogenic disease. These data indicate that we have developed new and robust models for studying severe ONNV disease and that HydroVax-CHIKV vaccination can protect against infection with a highly pathogenic contemporary strain of ONNV.<\/jats:p>","DOI":"10.1371\/journal.pntd.0012938","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:36:33Z","timestamp":1742232993000},"page":"e0012938","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Development of a virulent O\u2019nyong\u2019nyong challenge model to determine heterologous protection mediated by a hydrogen peroxide-inactivated chikungunya virus vaccine"],"prefix":"10.1371","volume":"19","author":[{"given":"Whitney C.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Streblow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi F.","family":"Andoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Denton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Rau\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Amanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig N.","family":"Kreklywich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Arduino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauthami","family":"Sulgey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalene M.","family":"Streblow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark T.","family":"Heise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-2492","authenticated-orcid":true,"given":"Daniel N.","family":"Streblow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"issue":"6","key":"pntd.0012938.ref001","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0035-9203(60)90025-0","article-title":"O\u2019nyong-nyong fever: An epidemic virus disease in East Africa 1. Introduction","volume":"54","author":"AJ Haddow","year":"1960","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"1","key":"pntd.0012938.ref002","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1006\/viro.1998.9437","article-title":"Emergence of epidemic O\u2019nyong-nyong fever in Uganda after a 35-year absence: genetic characterization of the virus","volume":"252","author":"RS Lanciotti","year":"1998","journal-title":"Virology"},{"issue":"5","key":"pntd.0012938.ref003","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1086\/313462","article-title":"O\u2019nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and validation of a clinical case definition for surveillance purposes","volume":"29","author":"N Kiwanuka","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pntd.0012938.ref004","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1086\/315073","article-title":"O\u2019nyong-nyong fever in south-central Uganda, 1996-1997: description of the epidemic and results of a household-based seroprevalence survey","volume":"180","author":"EJ Sanders","year":"1999","journal-title":"J Infect Dis"},{"issue":"8","key":"pntd.0012938.ref005","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.3201\/eid1208.060199","article-title":"O\u2019nyong-nyong virus, Chad","volume":"12","author":"M Bessaud","year":"2006","journal-title":"Emerging Infectious Diseases"},{"issue":"1","key":"pntd.0012938.ref006","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4269\/ajtmh.2005.73.1.0730032","article-title":"O\u2019Nyong-nyong fever in West Africa","volume":"73","author":"DL Posey","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"pntd.0012938.ref007","doi-asserted-by":"crossref","first-page":"e0011712","DOI":"10.1371\/journal.pntd.0011712","article-title":"Co-circulation of two Alphaviruses in Burkina Faso: Chikungunya and O\u2019nyong nyong viruses","volume":"18","author":"B Tinto","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0012938.ref008","doi-asserted-by":"crossref","first-page":"e0003436","DOI":"10.1371\/journal.pntd.0003436","article-title":"High rates of o\u2019nyong nyong and Chikungunya virus transmission in coastal Kenya","volume":"9","author":"AD LaBeaud","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0012938.ref009","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1038\/s41467-021-26707-9","article-title":"Model-based assessment of Chikungunya and O\u2019nyong-nyong virus circulation in Mali in a serological cross-reactivity context","volume":"12","author":"N Hoz\u00e9","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"pntd.0012938.ref010","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/v14061286","article-title":"Serological evidence of exposure to onyong-nyong and chikungunya viruses in febrile patients of rural taita-taveta county and urban kibera informal settlement in Nairobi, Kenya","volume":"14","author":"MM Masika","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"pntd.0012938.ref011","doi-asserted-by":"crossref","first-page":"2355201","DOI":"10.1080\/21505594.2024.2355201","article-title":"Pathogenicity and virulence of O\u2019nyong-nyong virus: A less studied Togaviridae with pandemic potential","volume":"15","author":"S Tong Jia Ming","year":"2024","journal-title":"Virulence"},{"issue":"3","key":"pntd.0012938.ref012","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7589\/2012-08-212","article-title":"Prevalence of antibodies to alphaviruses and flaviviruses in free-ranging game animals and nonhuman primates in the greater Congo basin","volume":"49","author":"RC Kading","year":"2013","journal-title":"J Wildl Dis"},{"issue":"9","key":"pntd.0012938.ref013","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1007\/s10067-020-05011-9","article-title":"Persistent chikungunya arthritis in Roraima, Brazil","volume":"39","author":"RLN Hayd","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"8","key":"pntd.0012938.ref014","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.3899\/jrheum.190162","article-title":"Chronic joint pain 3 years after chikungunya virus infection largely characterized by relapsing-remitting symptoms","volume":"47","author":"SR Tritsch","year":"2020","journal-title":"J Rheumatol"},{"issue":"8","key":"pntd.0012938.ref015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/tmi.13906","article-title":"Incidence and factors associated with chronic chikungunya arthritis following chikungunya virus infection","volume":"28","author":"P Yodtaweepornanan","year":"2023","journal-title":"Trop Med Int Health"},{"issue":"6","key":"pntd.0012938.ref016","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.4269\/ajtmh.12-0674","article-title":"The role of innate versus adaptive immune responses in a mouse model of O\u2019nyong-nyong virus infection","volume":"88","author":"RL Seymour","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"pntd.0012938.ref017","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/0035-9203(62)90144-X","article-title":"O\u2019nyong-nyong fever; an epidemic virus disease in East Africa. V human antibody studies by plaque inhibition and other serological tests.","volume":"56","author":"M Williams","year":"1962","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"10","key":"pntd.0012938.ref018","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/infdis\/jiz658","article-title":"Analysis of humoral immune responses in chikungunya virus (CHIKV)-infected patients and individuals vaccinated with a candidate CHIKV vaccine","volume":"221","author":"L Henss","year":"2020","journal-title":"J Infect Dis"},{"issue":"5","key":"pntd.0012938.ref019","doi-asserted-by":"crossref","first-page":"699-711.e7","DOI":"10.1016\/j.chom.2020.07.008","article-title":"Human mAbs broadly protect against arthritogenic alphaviruses by recognizing conserved elements of the Mxra8 receptor-binding site","volume":"28","author":"LA Powell","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"3","key":"pntd.0012938.ref020","doi-asserted-by":"crossref","first-page":"e0011154","DOI":"10.1371\/journal.pntd.0011154","article-title":"Infection with chikungunya virus confers heterotypic cross-neutralizing antibodies and memory B-cells against other arthritogenic alphaviruses predominantly through the B domain of the E2 glycoprotein","volume":"17","author":"JM Powers","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0012938.ref021","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/vaccines8020209","article-title":"Arthritogenic Alphavirus Vaccines: Serogrouping Versus Cross-Protection in Mouse Models","volume":"8","author":"W Nguyen","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"7","key":"pntd.0012938.ref022","doi-asserted-by":"crossref","first-page":"e1010695","DOI":"10.1371\/journal.ppat.1010695","article-title":"Development of a next-generation chikungunya virus vaccine based on the HydroVax platform","volume":"18","author":"DK Slifka","year":"2022","journal-title":"PLoS Pathog"},{"issue":"696","key":"pntd.0012938.ref023","doi-asserted-by":"crossref","first-page":"eade8273","DOI":"10.1126\/scitranslmed.ade8273","article-title":"A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans.","volume":"15","author":"S Raju","year":"2023","journal-title":"Science Translational Medicine"},{"issue":"8","key":"pntd.0012938.ref024","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3390\/vaccines12080893","article-title":"The approved live-attenuated chikungunya virus vaccine (IXCHIQ\u00ae) elicits cross-neutralizing antibody breadth extending to multiple arthritogenic alphaviruses similar to the antibody breadth following natural infection","volume":"12","author":"WC Weber","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"31","key":"pntd.0012938.ref025","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1016\/j.vaccine.2012.04.099","article-title":"Cross-protective immunity against o\u2019nyong-nyong virus afforded by a novel recombinant chikungunya vaccine","volume":"30","author":"CD Partidos","year":"2012","journal-title":"Vaccine"},{"issue":"12","key":"pntd.0012938.ref026","doi-asserted-by":"crossref","first-page":"e00692-22","DOI":"10.1128\/mra.00692-22","article-title":"Complete genome sequence of O\u2019nyong Nyong virus isolated from a febrile patient in 2017 in Uganda","volume":"11","author":"P Ledermann Jeremy","year":"2022","journal-title":"Microbiology Resource Announcements"},{"issue":"10","key":"pntd.0012938.ref027","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.1128\/JVI.80.10.4992-4997.2006","article-title":"Effects of an opal termination codon preceding the nsP4 gene sequence in the O\u2019Nyong-Nyong virus genome on Anopheles gambiae infectivity","volume":"80","author":"KM Myles","year":"2006","journal-title":"J Virol"},{"key":"pntd.0012938.ref028","article-title":"Discovery of a cell-active chikungunya virus nsP2 protease inhibitor using a covalent fragment-based screening approach","author":"EM Merten","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"pntd.0012938.ref029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cells12010100","article-title":"Deciphering the role of schwann cells in inflammatory peripheral neuropathies post alphavirus infection","volume":"12","author":"Y Bedoui","year":"2022","journal-title":"Cells"},{"key":"pntd.0012938.ref030","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3389\/fimmu.2020.00894","article-title":"Longitudinal [18F]FB-IL-2 PET imaging to assess the immunopathogenicity of O\u2019nyong-nyong virus infection","volume":"11","author":"Y-H Chan","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"pntd.0012938.ref031","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1172\/JCI40104","article-title":"Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages","volume":"120","author":"K Labadie","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"pntd.0012938.ref032","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.1202177","article-title":"A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice","volume":"190","author":"T-H Teo","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"pntd.0012938.ref033","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0923-2516(96)80591-7","article-title":"Antigenic relationship between chikungunya virus strains and o\u2019nyong nyong virus using monoclonal antibodies","volume":"146","author":"NK Blackburn","year":"1995","journal-title":"Res Virol"},{"issue":"3","key":"pntd.0012938.ref034","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF01317418","article-title":"A comparative study of O\u2019nyong nyong virus with Chikungunya virus and plaque variants","volume":"59","author":"AC Chanas","year":"1979","journal-title":"Arch Virol"},{"key":"pntd.0012938.ref035","article-title":"Chikungunya virus vaccines: A review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure","volume":"36","author":"W Weber","year":"2024","journal-title":"BioDrugs"},{"key":"pntd.0012938.ref036","author":"Food U, Administration D","year":"2023"},{"key":"pntd.0012938.ref037","volume-title":"First vaccine to protect adults from Chikungunya","author":"European Medicines Agency","year":"2024"},{"issue":"4","key":"pntd.0012938.ref038","first-page":"813-813.e1","article-title":"Live-attenuated chikungunya virus vaccine","volume":"187","author":"LFP Ng","year":"2024","journal-title":"Cell"},{"issue":"4","key":"pntd.0012938.ref039","doi-asserted-by":"crossref","first-page":"e02325-18","DOI":"10.1128\/AAC.02325-18","article-title":"Src family kinase inhibitors block translation of alphavirus subgenomic mRNAs","volume":"63","author":"R Broeckel","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"pntd.0012938.ref040","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajpath.2010.11.018","article-title":"A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence","volume":"178","author":"TE Morrison","year":"2011","journal-title":"Am J Pathol"},{"key":"pntd.0012938.ref041","volume-title":"A simple method of estimating fifty per cent endpoints","author":"LJ Reed","year":"1938"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012938","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012938","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:48:12Z","timestamp":1743637692000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012938"}},"subtitle":[],"editor":[{"given":"Ran","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012938","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]}}}